MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Danaher Corporation Accounts Payables 2011-2026 | DHR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.84 B | 1.75 B | 1.77 B | 1.86 B | 2.57 B | 2.05 B | 1.51 B | 1.71 B | 1.51 B | 1.48 B | 1.39 B | 1.82 B | 1.78 B | 1.55 B | 1.42 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.57 B | 1.39 B | 1.73 B |
Quarterly Accounts Payables Danaher Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 B | 1.75 B | - | - | - | 2.42 B | 2.36 B | 2.57 B | 2.13 B | 1.97 B | 2.57 B | 2.05 B | 2.05 B | 2.05 B | 2.05 B | 1.52 B | 1.51 B | 1.51 B | 1.51 B | 1.5 B | 1.71 B | 1.71 B | 1.71 B | 1.51 B | 1.51 B | 1.51 B | 1.51 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 1.39 B | 1.39 B | 2.05 B | 2.05 B | 1.82 B | 1.82 B | 1.88 B | 1.88 B | 1.74 B | 1.78 B | 1.78 B | 1.78 B | 1.55 B | 1.55 B | 1.55 B | 1.55 B | 1.42 B | 1.42 B | 1.42 B | 1.42 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.57 B | 1.39 B | 1.74 B |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biomerica
BMRA
|
295 K | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
 |
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
6.9 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
307 M | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
344 M | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
1.48 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
176 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M |  China |
 |
Fulgent Genetics
FLGT
|
18.4 M | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
Charles River Laboratories International
CRL
|
149 M | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
322 M | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
14 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
5.59 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
1.66 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
110 M | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
446 M | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
221 M | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
173 M | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
2.93 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
54.4 M | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
9.99 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
42.9 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
9.37 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
28.1 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
841 M | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Mettler-Toledo International
MTD
|
267 M | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
30 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
270 K | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
23.1 M | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
1.17 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
31.1 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
OPKO Health
OPK
|
47.1 M | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Pacific Biosciences of California
PACB
|
20.8 M | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
153 M | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | USA |